BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 17327378)

  • 21. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
    Apostolova G; Schweizer RA; Balazs Z; Kostadinova RM; Odermatt A
    Am J Physiol Endocrinol Metab; 2005 May; 288(5):E957-64. PubMed ID: 15613680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
    Rask E; Walker BR; Söderberg S; Livingstone DE; Eliasson M; Johnson O; Andrew R; Olsson T
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3330-6. PubMed ID: 12107245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
    Tomlinson JW; Finney J; Gay C; Hughes BA; Hughes SV; Stewart PM
    Diabetes; 2008 Oct; 57(10):2652-60. PubMed ID: 18633104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
    Srivastava RA
    Eur J Pharmacol; 2009 Apr; 607(1-3):258-63. PubMed ID: 19245804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients.
    Baudrand R; Domínguez JM; Carvajal CA; Riquelme A; Campino C; Macchiavello S; Bozinovic M; Morales M; Pizarro M; Solis N; Escalona A; Boza C; Arrese M; Fardella CE
    Metabolism; 2011 Dec; 60(12):1775-80. PubMed ID: 21704348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
    Jang C; Obeyesekere VR; Dilley RJ; Krozowski Z; Inder WJ; Alford FP
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3314-20. PubMed ID: 17519316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of hyperlipidemia on 11β-hydroxysteroid-dehydrogenase, glucocorticoid receptor, and leptin expression in insulin-sensitive tissues of cats.
    Sieber-Ruckstuhl NS; Zini E; Osto M; Franchini M; Boretti FS; Meli ML; Sigrist B; Lutz TA; Reusch CE
    Domest Anim Endocrinol; 2010 Nov; 39(4):222-30. PubMed ID: 20688460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
    Berger J; Tanen M; Elbrecht A; Hermanowski-Vosatka A; Moller DE; Wright SD; Thieringer R
    J Biol Chem; 2001 Apr; 276(16):12629-35. PubMed ID: 11278270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
    Sandeep TC; Andrew R; Homer NZ; Andrews RC; Smith K; Walker BR
    Diabetes; 2005 Mar; 54(3):872-9. PubMed ID: 15734867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
    Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
    Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
    Tsilchorozidou T; Honour JW; Conway GS
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
    Nakano S; Inada Y; Masuzaki H; Tanaka T; Yasue S; Ishii T; Arai N; Ebihara K; Hosoda K; Maruyama K; Yamazaki Y; Shibata N; Nakao K
    Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1213-22. PubMed ID: 17190905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peroxisome proliferator-activated receptor-γ activation induces 11β-hydroxysteroid dehydrogenase type 1 activity in human alternative macrophages.
    Chinetti-Gbaguidi G; Bouhlel MA; Copin C; Duhem C; Derudas B; Neve B; Noel B; Eeckhoute J; Lefebvre P; Seckl JR; Staels B
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):677-85. PubMed ID: 22207732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
    Berthiaume M; Laplante M; Tchernof A; Deshaies Y
    Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Obesity and Insulin on Tissue-Specific Recycling Between Cortisol and Cortisone in Men.
    Anderson AJ; Andrew R; Homer NZM; Hughes KA; Boyle LD; Nixon M; Karpe F; Stimson RH; Walker BR
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1206-e1220. PubMed ID: 33270115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue.
    Paulsen SK; Pedersen SB; Jørgensen JO; Fisker S; Christiansen JS; Flyvbjerg A; Richelsen B
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1093-8. PubMed ID: 16368752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
    Stewart PM; Toogood AA; Tomlinson JW
    Horm Res; 2001; 56 Suppl 1():1-6. PubMed ID: 11786677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.